Valeris

Policy updates are constant. Accuracy cannot slip. Policy Reporter by Valeris is using AI to support high-volume policy workflows, saving more than 1,500 agent hours while improving consistency and preserving human review. See how the right partner and the right tools can strengthen your policy intelligence operations. Learn more.

Our team is looking forward to joining industry leaders at the Asembia's AXS26 Summit! As the healthcare landscape grows more complex, alignment across market access, policy intelligence, and patient support is critical. Through Valeris, Triangle Insights Group by Valeris and Policy Reporter by Valeris, we drive connection and clarity where it's needed most, turning complexity into advantage - always with patients front and center. We're excited for the event and hope to see you there! Reach out to our team to schedule a private meeting or visit booth #1337 to connect with our team.

Market access is one of the most critical determinants of a successful pharmaceutical launch in the United States. However, developing an effective market access strategy has grown significantly more complex over the past decade. Rising healthcare costs, gaps in coverage from traditional health plans, and margin pressures for manufacturers have accelerated complexity as well as the demand for solutions that best serve patients and support industry-wide innovation. This perspective sets the foundation for Part 1 of a 6-part series from Triangle Insights Group by Valeris exploring evolving drug pricing and access dynamics in response to recent policy and reform, including the question: Is "net-first" pricing an impending strategic imperative or a policy-induced mirage? Read Part 1, linked in the comments, and follow along as the series continues to examine the forces shaping market access and pricing strategy.

5 weeks to 5 days. Because speed matters when patients are waiting. See how this was achieved. Full case study linked in the comments.

From Valeris: 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐁𝐞𝐧𝐞𝐟𝐢𝐭 𝐌𝐚𝐱𝐢𝐦𝐢𝐳𝐞𝐫𝐬 𝐀𝐫𝐞 𝐄𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐚𝐬 𝐚 𝐂𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐭 𝐅𝐨𝐫𝐜𝐞: 𝐖𝐡𝐚𝐭 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐞𝐫𝐬 𝐍𝐞𝐞𝐝 𝐭𝐨 𝐔𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝 Learn more about Valeris’ technology solutions and data analytics capabilities: https://drugch.nl/4bv62T0 Read the article: https://drugch.nl/4bmg0HJ #sponsored

When every day counts for patients starting therapy, delays aren’t just inconvenient, they can mean missed opportunities for care. In this case study, a slow, paper-heavy prior authorization process was leaving patients waiting and sometimes walking away before treatment began. A leading rare disease company partnered with Valeris to change that. With a new ePA platform and a dedicated support team, patients started therapy faster and workflows became simpler. Read the full case study, linked in the comments.

We’re excited to welcome Erin Solano as a Partner at Triangle Insights Group by Valeris. Erin brings extensive experience in life sciences consulting and has a proven track record supporting organizations across the pharmaceutical and biotech landscape, from early-stage innovators to global pharma leaders. Her expertise spans market access, pricing strategy, commercial strategy, and global product launches across a wide range of therapeutic areas. We look forward to the leadership and perspective Erin will bring as Triangle Insights Group continues to help life sciences organizations navigate complex challenges and drive meaningful impact. Read the full announcement: https://lnkd.in/ed9eU3QR

The shift toward Direct-to-Patient (DTP) models isn’t a trend - it’s quickly becoming standard practice across the industry, changing how patients engage with care and how life sciences companies deliver support.    At Valeris, we partner with life sciences companies to reach patients at the right place and time. In our upcoming series, Three Key Drivers in Direct-to-Patient, we’ll share more about the ways in which we deliver impact across direct-to-patient models.    Activation: Educating patients, supporting enrollment, and ensuring they are informed and eligible for DTP programs, accurately and on time.    Product Dispensing: Ensuring prescriptions reach patients at the right place and time, while keeping patient choice front and center.    Adherence: Engaging patients after dispense and addressing follow-up questions to maintain access and continuity of care.    Part One coming soon. Connect with our team to learn more.   

Our team is excited to attend Access USA and engage with industry leaders focused on advancing patient access and support. Our team will be onsite, onstage and hosting a private luncheon. If you're attending, we welcome the opportunity to connect! Swipe for details and reach out to our team onsite. Joe Abdalla, Robert (Rob) Brown, Blake Johnson, Victoria Glascott, Michael Harris, Molly Stallings, Terry Cato, Denise Von Dohren, Heather Smith, PhD, Mariam A., Edward Vegso, Michael Carlin, Matthew Haynes Informa Connect #AccessUSA

Part 2: Innovators in Affordability Series: The Intelligence Behind Patient Access With the expansion of affordability programs and the rise of sophisticated payer tactics, the life sciences industry entered an era where innovation alone was no longer enough. Valeris responded by building the compliance, integrity, and intelligence framework that now underpins the modern affordability ecosystem. This is part two of our story of innovation, built on experience, driven by intelligence, and designed for what’s next. Full paper linked in comments.